In the ongoing human effort to outmaneuver cancer's defenses, a Chinese clinical trial has offered a quietly significant finding: a two-drug combination targeting the HER2 protein from both inside and outside the cell achieved complete tumor elimination in 60% of women with advanced breast cancer before surgery. The neoPICD trial, conducted across seven centers in China, enrolled 108 evaluable patients and produced response rates that rival or exceed some current global standards. While the absence of a direct comparison group tempers certainty, the results invite a deeper question about wheth